Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody scanning method

Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics

(2016) Carlo Sala Frigerio et al.   Annual Review of Neuroscience

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Atomic Resolution Structure of Monomorphic Aβ42 Amyloid Fibrils

(2016) Michael T. Colvin et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s disease

(2016) Johnny Habchi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Atomic-resolution structure of a disease-relevant Aβ(1–42) amyloid fibril

(2016) Marielle Aulikki Wälti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation

(2016) Paolo Arosio et al.   Nature Communications

An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic A 42 aggregates linked with Alzheimers disease

(2016) J. Habchi et al.   Science Advances

A Rational Design Strategy for the Selective Activity Enhancement of a Molecular Chaperone toward a Target Substrate

(2015) Francesco A. Aprile et al.   BIOCHEMISTRY

The CamSol Method of Rational Design of Protein Mutants with Enhanced Solubility

(2015) Pietro Sormanni et al.   JOURNAL OF MOLECULAR BIOLOGY

N-Terminal Extensions Retard Aβ42 Fibril Formation but Allow Cross-Seeding and Coaggregation with Aβ42

(2015) Olga Szczepankiewicz et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers

(2015) Samuel I A Cohen et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structural and kinetic analysis of protein-aggregate strains in vivo using binary epitope mapping

(2015) Johan Bergh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins

(2015) Pietro Sormanni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting disordered proteins with small molecules using entropy

(2015) Gabriella T. Heller et al.   TRENDS IN BIOCHEMICAL SCIENCES

A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers

(2015) Samuel I A Cohen et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

(2014) Eric Karran et al.   ANNALS OF NEUROLOGY

The amyloid state and its association with protein misfolding diseases

(2014) Tuomas P. J. Knowles et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Chemical kinetics for drug discovery to combat protein aggregation diseases

(2014) Paolo Arosio et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Proliferation of amyloid- 42 aggregates occurs through a secondary nucleation mechanism

(2013) S. I. A. Cohen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

Toward aggregation-resistant antibodies by design

(2013) Christine C. Lee et al.   TRENDS IN BIOTECHNOLOGY

Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein

(2012) Nunilo Cremades et al.   CELL

From Macroscopic Measurements to Microscopic Mechanisms of Protein Aggregation

(2012) Samuel I.A. Cohen et al.   JOURNAL OF MOLECULAR BIOLOGY

Synthetic antibodies: Concepts, potential and practical considerations

(2012) S. Miersch et al.   METHODS

Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease

(2012) Gawain McColl et al.   Molecular Neurodegeneration

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

(2012) Iryna Benilova et al.   NATURE NEUROSCIENCE

Rational design of potent domain antibody inhibitors of amyloid fibril assembly

(2012) A. R. A. Ladiwala et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Introduction to current and future protein therapeutics: A protein engineering perspective

(2011) Paul J. Carter   EXPERIMENTAL CELL RESEARCH

Antibody-based therapy in Alzheimer's disease

(2011) Refik Pul et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Therapeutic antibodies: Market considerations, disease targets and bioprocessing

(2011) John G. Elvin et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Beyond natural antibodies: the power of in vitro display technologies

(2011) Andrew R M Bradbury et al.   NATURE BIOTECHNOLOGY

Protein aggregation diseases: pathogenicity and therapeutic perspectives

(2010) Adriano Aguzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

Sales of biologics to show robust growth through to 2013

(2009) Michael Goodman   NATURE REVIEWS DRUG DISCOVERY

An Analytical Solution to the Kinetics of Breakable Filament Assembly

(2009) T. P. J. Knowles et al.   SCIENCE

C. elegans Model Identifies Genetic Modifiers of α-Synuclein Inclusion Formation During Aging

(2008) Tjakko J. van Ham et al.   PLoS Genetics

Protein therapeutics: a summary and pharmacological classification

(2007) Benjamin Leader et al.   NATURE REVIEWS DRUG DISCOVERY